Our History

서브메인이미지

We seek to grow our business through the addition of a research platform to our established development platform.

  • 2020
    • 02

      In-licensing agreement for our back-eye disease drug candidate

    2019
    • 12

      Listed on the KOSDAQ

    • 07

      Out-licensing agreement of BBT-877 with Boehringer Ingelheim

    • 04

      BBT-401 first administered to patients in Phase 2 clinical studies in the United States

    • 03

      Series C closed

    • 02

      Initiated Phase 1 clinical trial for BBT-877 in the United States

    • 01

      FDA orphan drug designation for BBT-877 (IPF) In-licensing agreement for BBT-176

    2018
    • 12

      Out-licensing agreement for BBT-401 with Daewoong Pharmaceuticals (22 Asian countries)

    • 10

      Completed Phase 1 clinical studies for BBT-401

    • 05

      In-licensing agreement for BBT-931

    2017
    • 09

      Series B closed

    • 05

      In-licensing agreement for BBT-877

  • 2016
    • 12

      Establishment of our US subsidiary

    • 07

      Series A closed

    2015
    • 10

      In-licensing agreement for BBT-401

    • 09

      Corporate establishment